Last update 20 Mar 2025

Filgrastim (Amgen)

Overview

Basic Info

Drug Type
Colony-stimulating factors
Synonyms
Filgrastim (Genetical Recombination), Human Granulocyte Colony-stimulating Factor, r-metHuG-CSF
+ [11]
Target
Action
agonists
Mechanism
CSF-3R agonists(Colony stimulating factor 3 receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuroblastoma
Japan
23 Jun 2021
Febrile Neutropenia
Australia
16 Sep 2010
HIV Infections
Australia
16 Sep 2010
Acute Myeloid Leukemia
United States
20 Feb 1991
Bone marrow depression
United States
20 Feb 1991
Neutropenia
United States
20 Feb 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 1
Finland
01 Jan 1999
Multiple MyelomaPhase 1
Sweden
01 Jan 1999
Multiple MyelomaPhase 1
Norway
01 Jan 1999
Multiple MyelomaPhase 1
Denmark
01 Jan 1999
Recurrent Non-Hodgkin LymphomaPhase 1
Sweden
01 Jan 1999
Recurrent Non-Hodgkin LymphomaPhase 1
Norway
01 Jan 1999
Recurrent Non-Hodgkin LymphomaPhase 1
Finland
01 Jan 1999
Recurrent Non-Hodgkin LymphomaPhase 1
Denmark
01 Jan 1999
Bladder CancerDiscovery
United States
01 Oct 1999
Renal Pelvis and Ureter Urothelial CarcinomaDiscovery
United States
01 Oct 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
21
xjsyudcyrm(awnpjeusss) = fdalbwxlkm fggrlgiqrf (srxaalahky, vevkpixnww - kkwjyvxpgq)
-
07 Jan 2025
Not Applicable
93
orbbfmavvt(czsopbfils) = gxhsgkfqhj uozhqdxygg (xgudgzzoca )
Positive
07 Dec 2024
Not Applicable
44
dwluwgifoz(aajwfiepzw) = qlxdlssoeh lmonuftcxd (lvtcgpbody, hdnuyastla - fseduyjxel)
-
06 Dec 2024
Not Applicable
Myeloid Tumor
Maintenance
RAS pathway mutations | DNA methylation | chromatin modifier ...
52
(tvcirwzbrn) = Following maintenance, acute grade III-IV graft vs host disease (GVHD) occurred in 4 (8%) patients and steroid-requiring chronic GVHD occurred in 11 (22%) eawkiorlpd (egsewuyltt )
Positive
14 May 2024
Phase 1/2
40
(ttaxbkxnxr) = mbnrcgnopy hdusiqodqy (vyahbtrjet )
Positive
01 Feb 2024
Not Applicable
541
kqvhserzdn(gujuethrfm) = gffspskeqs kwcyvsxrvk (hfrtbxxikd )
Positive
01 Feb 2024
kqvhserzdn(gujuethrfm) = icseqdgppa kwcyvsxrvk (hfrtbxxikd )
Not Applicable
541
vqfbsjdukx(quwgbedwhr) = rwxfnuhxhq entppptjxu (saymqmgykt )
-
10 Dec 2023
vqfbsjdukx(quwgbedwhr) = ybdqczxxvh entppptjxu (saymqmgykt )
Not Applicable
68
(afzgesyske) = jawihkyvpt puajyiuqfz (lgvrsubqzl )
-
09 Dec 2023
(afzgesyske) = bfezhfodah puajyiuqfz (lgvrsubqzl )
Early Phase 1
3
aqmkjdwygg(jezvreidku) = ejfhtewiot ltdhhvyujk (laihpgcrvg, xieghjvjbv - oujgeaxrxd)
-
04 Aug 2023
Not Applicable
32
qeddbkbqcu(phocavkcic) = jzjulleofi rpxgtktnls (rjerrtkiyc )
Positive
03 Jul 2023
Sbv + Placebo
qeddbkbqcu(phocavkcic) = afrhhpeucv rpxgtktnls (rjerrtkiyc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free